期刊文献+

冠状动脉内注射替罗非班在经皮冠状动脉介入术中无复流治疗的临床研究 被引量:6

下载PDF
导出
摘要 目的观察替罗非班对经皮冠状动脉介入(PCI)术中无复流的治疗效果。方法PCI术中无复流的患者42例,随机分为替罗非班治疗组(n=21)和对照组(n=21),观察用药后靶血管前向血流的TIMI分级情况、心电图变化情况和主要终点事件的发生情况。结果替罗非班组术后靶血管TIMI血流明显高于对照组(P<0.05),差异有统计学意义,术后90 min心电图明显改善,1周内主要终点事件中死亡、顽固性缺血、再次心肌梗死发生率明显低于对照组(P<0.05),严重出血并发症发生率两组无明显差异。结论替罗非班可以有效改善PCI术中无复流现象并减少术后1周内主要终点事件发生,不会增加严重出血并发症。
出处 《微创医学》 2009年第6期648-649,共2页 Journal of Minimally Invasive Medicine
  • 相关文献

参考文献6

二级参考文献33

  • 1王风,王虹.冠心病现代治疗策略[J].广西医学,2005,27(3):311-313. 被引量:6
  • 2马依彤,陈铀,杨毅宁,黄定,马翔.国产替罗非班治疗急性冠脉综合征行PCI术患者的临床效果[J].心脏杂志,2007,19(2):189-191. 被引量:2
  • 3[1]Peerlinck K,De Lepeleire I,Goldberg M,et al.MK-383(L-700,46 2),a selective nonpeptide platelet glycoprotein Ⅱb/Ⅲa antagonist,is active in man[J].Circulation,1993,88(4,Part1)∶1512-1517.
  • 4[2]Joseph J,Lynch JR,Jacquelynn JC,et al.Nonpeptide glycoprotein Ⅱb/Ⅲa inhibitors.5.antithrombotic effects of MK-0383[J].J Pharmacol Exp Ther ,1995,272(1)∶20-32.
  • 5[3]FDA.MERCK&CO.,INC.West Point,PA 19486,USA [EB/OL].http://www.fda.gov/cd er/foi/label/1998/20913lbl.pdf.2000-08-15.
  • 6[4]FDA.NDA#20-912 Aggrastat Medical/Stastical Review [EB/OL].http://www.f da.gov/cardiovascular and renal drugs advisory committee.html.1998-02-15.
  • 7[5]Alexander JH,Harrington RA.Recent antiplatelet drug trails in the acute c ornary syndromes[J].Drugs,1998,56(6)∶965-976.
  • 8[6]McClellan KJ,Goa KL.Tirofiban[J].Drugs,1998,56(6)∶1067- 1080.
  • 9[1]Elmouchi DA,Bates ER.Platelet glycoprotein Ⅱb/Ⅲa inhibitor therapy in non-ST segment elevation acute coronary syndromes[J].Minerva Cardioangiol,2003,51 (5):547-560.
  • 10[2]Valgimigli M,Percoco G,Malagutti P,et al.Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial[J].JAMA,2005,293 (17):2109-2117.

共引文献199

同被引文献48

  • 1卢竞前,杨锋,李易,李建美,吕云,洪云飞,李玉,张荣华,吴燕.国产替罗非班在易化PCI治疗急性心肌梗死中应用观察[J].中国急救医学,2006,26(5):384-385. 被引量:2
  • 2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2149
  • 3李南,祖晓麟,颜红兵.替罗非班在急性非ST段抬高心肌梗死介入治疗中的安全性和有效性[J].第二军医大学学报,2007,28(5):524-526. 被引量:14
  • 4Sejersten M, Valeurn, Grande P, et al. Long - term prog- nostic value of ST - segment resolution in patients treated with fibrinolysis or primary percutaneous coronary interven- tion results from the DNA AMI - (DA) Nish trial in acute myocardial infarction. J Am Coll Cardiol,2009,54(6) :1763 - 1769.
  • 5Long SS,Stevenson DK. Reducing candida infections during neonatal intensive care:management choices,infection control,and fluconazole prophylaxis[J].Journal of Pediatrics,2005,(02):135-141.
  • 6Chang MR,Correia FP,Costa LC. Candida bloodstream infection:data from a teaching hospital in Mato Grosso do Sul,Brazil[J].REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO,2008,(05):265-268.
  • 7Villar CC,Kashleva H,Nobile CJ. Mucosal tissue invasion by Candida albicans is associated with E-cadherin degradation,mediated by transcription factor Rim101p and protease Sap5p[J].Infection and Immunity,2007,(05):2126-2135.
  • 8Murad AM,d'enfert C,Gaillardin C. Transcript profiling in Candida albicans reveals new cellular functions for the transcriptional repressors CaTup1,CaMig1 and CaNrg1[J].Molecular Microbiology,2001,(04):981-993.
  • 9Tongchusak S,Leelayuwat C,Brusic V. In silico prediction and immunological validation of common HLA-DRB1-restricted T cell epitopes of Candida albicans secretory aspartyl proteinase 2[J].Microbiology and Immunology,2008,(04):231-242.
  • 10Degel B,Staib P,Rohrer S. Cis-Configured aziridines are new pseudo-irreversible dual-mode inhibitors of Candida albicans secreted aspartic protease 2[J].Chem Med Chem,2008,(02):302-315.

引证文献6

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部